Predicting serotonin toxicity in serotonin reuptake inhibitor overdose

References

• Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol. 2005;28(5):205–214.
   PubMed Web of Science ®Google Scholar
• Isbister GK, Bowe SJ, Dawson A, et al. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277–285.
   PubMed Web of Science ®Google Scholar
• Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. 2007;187(6):361–365.
   PubMed Web of Science ®Google Scholar
• Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112–1120.
   PubMed Web of Science ®Google Scholar
• Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705–713.
   PubMed Web of Science ®Google Scholar
• Dunkley EJ, Isbister GK, Sibbritt D, et al. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635–642.
   PubMed Web of Science ®Google Scholar
• Nisijima K, Yoshino T, Yui K, et al. Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res. 2001;890(1):23–31.
   PubMed Web of Science ®Google Scholar
• Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry. 2006;59(11):1046–1051.
   PubMed Web of Science ®Google Scholar
• Watson WA, Litovitz TL, Rodgers GC, Jr., et al. 2004 Annual report of the American association of poison control centers toxic exposure surveillance system. Am J Emerg Med. 2005;23(5):589–666.
   PubMed Web of Science ®Google Scholar
• Asch DA, Parker RM. The libby zion case. One step forward or two steps backward? N Engl J Med. 1988;318(12):771–775.
   PubMed Web of Science ®Google Scholar
• Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ. 2002;325(7376):1332–1333.
   PubMed Web of Science ®Google Scholar
• Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM. 2003;96(5):369–374.
   PubMed Web of Science ®Google Scholar
• Chan AN, Gunja N, Ryan CJ. A comparison of venlafaxine and SSRIs in deliberate self-poisoning. J Med Toxicol. 2010;6(2):116–121.
   PubMedGoogle Scholar
• Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricylic antidepressants: a meta-analysis. Int Clin Psychopharmacol. 1995;9(4):33–40.
   PubMedGoogle Scholar
• Burra TA, Chen E, McIntyre RS, et al. Predictors of self-reported antidepressant adherence. Behav Med. 2007;32(4):127–134.
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders – III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol. 1998;12(3B):S55–S87.
   PubMedGoogle Scholar
• Murphy GM, Jr., Kremer C, Rodrigues HE, et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry. 2003;160(10):1830–1835.
   PubMed Web of Science ®Google Scholar
• Roberts RL, Mulder RT, Joyce PR, et al. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol. 2004;19(1):17–23.
   PubMed Web of Science ®Google Scholar
• Sugai T, Suzuki Y, Sawamura K, et al. The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J. 2006;6(5):351–356.
   PubMed Web of Science ®Google Scholar
• Kato M, Fukuda T, Wakeno M, et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology. 2006;53(4):186–195.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Kobayashi D, Murakami Y, et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol. 2008;11(2):261–267.
   PubMed Web of Science ®Google Scholar
• Murphy GM, Jr., Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61(11):1163–1169.
   PubMed Web of Science ®Google Scholar
• Cooper JM, Newby DA, Whyte IM, et al. Serotonin toxicity from antidepressant overdose and its association with the T102C polymorphism of the 5-HT2A receptor. Pharmacogenomics J. 2014;14(4):390–394.
   PubMed Web of Science ®Google Scholar
• Cooper JM, Duffull SB, Saiao AS, et al. The pharmacokinetics of sertraline in overdose and the effect of activated charcoal. Br J Clin Pharmacol. 2015;79(2):307–315.
   PubMed Web of Science ®Google Scholar
• Kumar VVP, Oscarsson S, Friberg LE, et al. The effect of decontamination procedures on the pharmacokinetics of venlafaxine in overdose. Clin Pharmacol Ther. 2009;86(4):403–410.
   PubMed Web of Science ®Google Scholar
• Friberg LE, Isbister GK, Hackett LP, et al. The population pharmacokinetics of citalopram after deliberate self-poisoning: a bayesian approach. J Pharmacokinet Pharmacodyn. 2005;32(3–4):571–605.
   PubMed Web of Science ®Google Scholar
• Hudson D, Djogovic D. Alternate venlafaxine kinetics in overdose patients. J Clin Pharm Ther. 2007;32(1):109.
   PubMed Web of Science ®Google Scholar
• Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16(4):615–619.
   PubMedGoogle Scholar
• Lappin RI, Auchincloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med. 1994;331(15):1021–1022.
   PubMed Web of Science ®Google Scholar
• Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13(1):100–109.
   PubMed Web of Science ®Google Scholar
• Nisijima K, Yoshino T, Ishiguro T. Risperidone counteracts lethality in an animal model of the serotonin syndrome. Psychopharmacology. 2000;150(1):9–14.
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment - definitions and general considerations. Oslo, Norway, 2016. Available from: http://www.whocc.no/ddd/definition_and_general_considera/
   Google Scholar
• Page CB, Duffull SB, Whyte IM, et al. Promethazine overdose: clinical effects, predicting delirium and the effect of charcoal. QJM. 2009;102(2):123–131.
   PubMed Web of Science ®Google Scholar
• Kumar VV, Isbister GK, Duffull SB. The effect of decontamination procedures on the pharmacodynamics of venlafaxine in overdose. Br J Clin Pharmacol. 2011;72(1):125–132.
   PubMed Web of Science ®Google Scholar
• Isbister GK, Duffull SB. Quetiapine overdose: predicting intubation, duration of ventilation, cardiac monitoring and the effect of activated charcoal. Int Clin Psychopharmacol. 2009;24(4):174–180.
   PubMed Web of Science ®Google Scholar
• Isbister GK, Hackett LP, Dawson AH, et al. Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol. 2003;56(4):441–450.
   PubMed Web of Science ®Google Scholar
• Choi YK, Moran-Gates T, Gardner MP, et al. Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats. Eur Neuropsychopharmacol. 2010;20(3):187–194.
   PubMed Web of Science ®Google Scholar
• Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 1996;124(1–2):57–73.
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68(1):29–39.
   PubMed Web of Science ®Google Scholar
• Isbister GK, Friberg LE, Stokes B, et al. Activated charcoal decreases the risk of QT prolongation after citalopram overdose. Ann Emerg Med. 2007;50(5):593–600.
   PubMed Web of Science ®Google Scholar